EGF, or epidermal growth factor, is a small protein your body naturally produces to signal cells to grow, divide, and repair themselves. It plays a central role in wound healing, skin renewal, and tissue maintenance. You’ve likely come across the term on a skincare product label, but EGF is far more than a cosmetic ingredient. It’s a fundamental biological signal that, when functioning normally, keeps your tissues healthy, and when malfunctioning, can contribute to cancer.
How EGF Works in Your Body
EGF is a signaling molecule. It works by binding to a specific receptor on the surface of your cells called the EGF receptor (EGFR), which acts as a switch for cell growth and division. When EGF locks onto this receptor, it triggers a cascade of internal signals that tell the cell to multiply, migrate to a new location, or specialize into a particular cell type.
Your body produces EGF in several tissues and secretes it into fluids including saliva, breast milk, urine, tears, and amniotic fluid. In saliva alone, EGF helps explain why minor mouth wounds tend to heal remarkably fast. The protein exists in several molecular sizes across these fluids, though one standard form accounts for more than 90% of the EGF found in most of them.
The discovery of EGF earned American biochemist Stanley Cohen a share of the 1986 Nobel Prize in Physiology or Medicine. His work, alongside Rita Levi-Montalcini’s discovery of nerve growth factor, revealed for the first time how the body regulates cell growth at a molecular level.
EGF’s Role in Wound Healing
One of EGF’s most important jobs is coordinating tissue repair. When you cut or burn your skin, EGF helps recruit new cells to the wound site, stimulates them to divide, and promotes the formation of new tissue. This has made synthetic (recombinant) versions of EGF a subject of serious medical interest, particularly for chronic wounds that resist normal healing.
Diabetic foot ulcers are a major area of research. A meta-analysis of randomized controlled trials found that applying recombinant human EGF topically to diabetic foot ulcers increased the likelihood of healing by 54% compared to standard care alone. For mild to moderate ulcers (lower severity grades), the benefit was even more pronounced, with a 61% improvement in healing rates. For more severe ulcers, injecting EGF directly into the wound bed showed promise as well, though the evidence there is less robust. These findings have led several countries to approve EGF-based wound treatments, particularly for diabetic patients at risk of amputation.
EGF in Skincare Products
The same properties that make EGF useful in wound healing have made it attractive to the cosmetics industry. EGF serums and creams are marketed as anti-aging treatments, and there is some early evidence behind the claims. Lab studies show that recombinant EGF boosts the production of collagen (the protein that keeps skin firm) and hyaluronic acid (which keeps skin hydrated) in aged skin cells. It also reduces the activity of enzymes that break down collagen, which is one of the main drivers of wrinkles.
Small human studies have shown visible improvements. In one trial, 29 women who applied an EGF-containing serum for three months saw improvements in skin texture, pore size, wrinkles, and brown spots. Another study found that a four-week EGF cream reduced wrinkles around the eyes in 20 women, though the EGF needed to be delivered through micro-spicules (tiny needles in the cream) to penetrate effectively. A microneedle patch containing EGF also outperformed the same patch without it for wrinkle reduction and hydration.
The catch: these studies are small, most lack proper control groups, and the overall clinical evidence remains unclear. EGF is a large protein molecule that doesn’t easily penetrate intact skin on its own, which is why delivery methods like microneedles and micro-spicules keep appearing in the research. A basic EGF serum applied to the surface may not deliver enough of the protein to deeper skin layers where it would need to act. There is also no widely established effective concentration for over-the-counter EGF products, making it difficult to compare what’s on the market.
How EGF Differs From Other Growth Factors
EGF isn’t the only growth factor involved in skin health. Two others you’ll encounter in skincare and biology are FGF (fibroblast growth factor) and TGF-beta (transforming growth factor beta). Each has a distinct role. FGF and TGF-beta are considered the primary regulators of skin development from the earliest stages, controlling how skin cells form, migrate, and differentiate during embryonic development and regeneration. Researchers have even generated human skin in the lab by manipulating just these two signaling pathways.
EGF’s specialty is promoting the growth of the outermost skin layer, the epidermis. Interestingly, both EGF and a related growth factor called KGF (keratinocyte growth factor) have been shown to block hair follicle formation and instead push developing skin cells toward becoming regular surface skin. So while TGF-beta and FGF shape the deeper architecture and specialized structures of skin, EGF focuses on surface-level renewal and repair.
The Cancer Connection
The same growth-promoting properties that make EGF essential for healing also make its receptor, EGFR, dangerous when it malfunctions. Normally, EGFR activation is tightly controlled. The receptor sits quietly on the cell surface until EGF binds to it. But mutations or overexpression of EGFR can leave the switch stuck in the “on” position, driving cells to multiply uncontrollably.
EGFR overexpression or mutation has been found in lung cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancers, melanoma, and glioblastoma (an aggressive brain tumor). In some cases, as few as five specific mutations in the receptor are enough to convert it from a quiet, well-regulated protein into one that drives tumor growth without any EGF signal at all.
This understanding has led to an entire class of cancer drugs designed to block EGFR. These fall into two categories. The first is small-molecule inhibitors that block the receptor’s activity from inside the cell. Multiple generations of these drugs now exist, with newer versions designed to overcome resistance that tumors develop to earlier ones. The second category is antibody-based drugs that physically block the outside of the receptor, preventing it from activating. Both approaches are used in clinical practice for cancers driven by EGFR overactivity, and identifying EGFR mutations in a tumor often determines which treatment a patient receives.
This cancer link is also why some dermatologists and researchers urge caution about long-term topical EGF use. While no direct evidence has connected EGF skincare products to cancer development in humans, the biological rationale for concern exists: you’re applying a growth-promoting signal to skin that may already contain precancerous cells. The doses in cosmetic products are far lower than what drives tumor growth internally, but long-term safety data simply doesn’t exist yet.